Biopharmaceutical Excipients Market (2nd Edition): Industry Trends and Global Forecasts: Distribution by Scale of Operation, Type of Modality, Type of Excipient, Chemical Components, Company Size, Source of Manufacturing, End User and Geographical Regions

The global biopharmaceutical excipients market is estimated to grow from USD 3.6 billion in the current year to USD 6.3 billion by 2035, at a CAGR of 6.4% during the forecast period, till 2035.

Scale of Operation

Preclinical / Clinical Scale
Commercial Scale

Type of Modality

Antibodies
Vaccines
Cell and Gene Therapies
Proteins / Peptides
Other Biologics

Type of Excipients

Buffering Agents
Lyoprotectant Agents
Solubilizers and Surfactants
Tonicity Agents
pH Adjusting Agents
Others

Chemical Components

Carbohydrates
Polymers
Polyols
Proteins / Amino Acids
Others

Company Size

Small Players
Mid-sized Players
Large and Very Large Players

Source of Manufacturing

In-house
Outsourcing

End User

Contract Manufacturers
Drug Developers
Hybrid Players

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

BIOPHARMACEUTICAL EXCIPIENTS MARKET: GROWTH AND TRENDS

Over the years, the increasing popularity of biologics has resulted in a significant shift within the healthcare sector. In the past ten years, the annual rate of biopharmaceutical approvals (which includes monoclonal antibodies, recombinant proteins, vaccines, and gene therapies) by the USFDA has consistently risen, with biologics accounting for over 40% of all newly approved drugs. As of October 2024, there are more than 12,700 biologic products undergoing clinical trials globally, emphasizing the level of innovation in this area. Considering their unique advantages over small molecules such as improved efficacy, precise targeting, and better safety profiles, biologics are projected to continue propelling advancements in treatments for cancer, autoimmune diseases, rare disorders, and genetic conditions.

Nevertheless, biologics possess a complex structure and are naturally less stable than small molecules, making them susceptible to physical degradation (such as aggregation, precipitation, and denaturation) and chemical degradation (including oxidation, deamidation, and hydrolysis). To overcome these challenges, various biopharmaceutical excipients, such as sugars (including sucrose and trehalose), amino acids (such as arginine), surfactants (for example, polysorbates), and polymeric agents (like PEGs), are employed to stabilize formulations, increase solubility, regulate pH and tonicity, and enhance overall bioavailability. In fact, more than 70% of marketed biologics depend on polysorbates as stabilizing agents, while bulking agents, antioxidants, and preservatives enhance their functional effectiveness. Further, excipients have become essential for facilitating advanced drug product formats, including lyophilized vials, prefilled syringes, and ready-to-use liquid formulations. Ongoing innovations, especially in lipid-based excipients for mRNA vaccines and therapeutics, are expanding the landscape of excipients even further. Combined with the increasing tendency towards outsourcing and enhanced regulatory support for innovative excipients, the application of biopharmaceutical excipients is set for continued market growth throughout the forecast period.

BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY INSIGHTS

The report delves into the current state of the biopharmaceutical excipients market and identifies potential growth opportunities within the industry. Some key findings from the report include:

The current market landscape features the presence of close to 60 manufacturers that claim to offer services for biopharmaceutical excipients across the world; of these, majority (40%) are headquartered in Europe.

Close to 50% of the companies manufacture polymer-based biopharmaceutical excipients; of these, majority (~65%) of the excipients are being used as stabilizers in drug formulations.
Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the biopharmaceutical excipients manufacturing domain.
Majority of the deals inked in this domain were distribution agreements, indicating a strategic focus on expanding market reach and ensuring broad availability of specialized excipients across diverse geographic regions.

Driven by the growing demand for biologics, CMOs have significantly expanded their existing capacities and capabilities; notably, majority of the expansion initiatives have been undertaken by players based in Europe.
Our proprietary framework serves as a strategic tool for developers, enabling them to evaluate vendors based on their specific requirements for biopharmaceutical excipients manufacturing.
Driven by the growing adoption of biologic therapies, innovations in multifunctional excipients, the biopharmaceutical excipients market is anticipated to witness robust growth in the coming years.
Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.

Carbohydrates sub-segment is estimated to capture most of the market share in the current year, due to the extensive use of starch, sucrose, and dextrose in drug formulations as stabilizers and bulking agents for biologics.

BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY SEGMENTS

Commercial Scale of Operation Accounts for the Largest Share of Biopharmaceutical Excipients Market

In terms of scale of operation, the biopharmaceutical excipients market is segmented across preclinical / clinical and commercial scale. In the current year, the commercial scale segment occupies the higher biopharmaceutical excipients market share (close to 90%) and is likely to grow at a higher CAGR (6.8%) during the forecast period. This dominance is fueled by the increased demand for biologics, necessitating substantial amounts of excipients to maintain product stability, solubility, and efficacy during large-scale production. With an increasing number of biologic drugs moving into commercial manufacturing phases, the demand for excipients rises significantly, leading to a larger market share for commercial-scale operations.

Solid Tumors Segment to Hold the Highest Revenue in the Biopharmaceutical Excipient Market

In the current year, antibodies segment constitutes most of the biopharmaceutical excipient market size (around 50%) and is likely to grow at a higher CAGR (8.7%) during the forecast period. This results from the swift expansion and mass manufacturing of monoclonal antibodies and antibody-driven therapies, necessitating various excipients to maintain the stability, solubility, and safety of these intricate biologics.

Europe Accounts for the Largest Share of the Biopharmaceutical Excipients Market

In terms of geographical regions, Europe is likely to capture majority (35%) of the biopharmaceutical excipients market share in the current year, and this trend is unlikely to change in the future as well. This results from the significant presence of well-established biotech and pharmaceutical firms in the sector. The focus of major industry leaders drives substantial funding and speeds up the integration of AI technologies in pharmaceutical production. Further, this sector gains advantages from its developed pharmaceutical ecosystem, strong R&D capacities, and favorable regulatory framework, which enhances its leading position. Significantly, the Asia-Pacific market is expected to expand to the highest CAGR (7.7%) throughout the forecast period until 2035.

Example Players in the Biopharmaceutical Excipients Market

Avantor
Spectrum Chemical Manufacturing
Actylis
Pfanstiehl
Biospectra
BOC Sciences
Merck KGaA
CG Chemkalien
Evonik
BASF Pharma
Mass Chemicals
Gangwal
Mitushi Biopharma
Nagase Vitta

BIOPHARMACEUTICAL EXCIPIENTS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biopharmaceutical excipients market, focusing on key market segments, including [A] type of modality, [B] type of excipient, [C] chemical components, [D] company size, [E] source of manufacturing, [F] end user and [G] key geographical regions.
Market Landscape: A comprehensive evaluation of biopharmaceutical excipients companies, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facilities, [E] type of excipient, [F] scale of operation, [G] type of formulation, [H] type of biologic and [I] global regulatory compliance.
Company Profiles: In-depth profiles of companies engaged in the manufacturing of biopharmaceutical excipients headquartered in North America, Europe and Asia-Pacific focusing on [A] company overview, [B] biopharmaceutical excipient offering, [C] recent developments and [D] an informed future outlook.
Company Competitiveness Analysis: A comprehensive competitive analysis of biopharmaceutical manufacturers, examining factors, such as supplier strength, service strength and number of manufacturing facilities.
Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders in the biopharmaceutical excipients market based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C], year and type of partnership and [D], geographical distribution of partnership activity.
Recent Expansions: A detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] type of excipient, [D] type of expansion (region and country), [E] location of expanded facility (region), [F] location of expanded facility (country), [G] most active players (in terms of number of recent expansions) and [H] geographical distribution (region and country).
Capacity Analysis: An estimate of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as [A] company size, [B] scale of operation and [C] key geographical regions.
Vendor Selection Framework: An insightful vendor selection framework highlighting the parameters that should be considered when outsourcing biopharmaceutical excipients manufacturing operations.
Market Impact Analysis: In-depth analysis of the factors that can impact the growth of the biopharmaceutical excipients market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs Covering All Analytical Modules
Up to 15% Complimentary Content Customization
In-Depth Report Walkthrough with the Research Team
Complimentary Report Update if the Report is 6+ Months Old

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Biopharmaceutical Excipients
6.3. Properties of Ideal Excipients
6.4. Classification of Biopharmaceutical Excipients
6.4.1. Classification of Excipients based on Route of Administration
6.4.2. Classification of Excipients based on Structure
6.4.3. Classification of Excipients based on Function
6.4.4. Classification of Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
6.5. Applications of Biopharmaceutical Excipients
6.6. Regulatory Scenario
6.7. Concluding Remarks

7. MARKET LANDSCAPE: BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURERS

7.1. Chapter Overview
7.2. Biopharmaceutical Excipients Manufacturers: Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Location of Headquarters and Company Size
7.2.5. Analysis by Location of Manufacturing Facilities (Region)
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Type of Excipient based on Chemical Composition
7.2.8. Analysis by Type of Excipient based on Function
7.2.9. Analysis by Type of Chemical Structure of Excipient
7.2.10. Analysis by Type of Formulation
7.2.11. Analysis by Type of Biologic
7.2.12. Analysis by Global Regulatory Compliance

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Overview of Peer Groups
8.5. Company Competitiveness Analysis
8.5.1. Biopharmaceutical Excipient Manufacturers Headquartered in North America
8.5.2. Biopharmaceutical Excipient Manufacturers Headquartered in Europe
8.5.3. Biopharmaceutical Excipient Manufacturers Headquartered in Asia-Pacific

9. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

9.1. Chapter Overview
9.2. Avantor
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Biopharmaceutical Excipient Offerings
9.2.4. Manufacturing Facilities
9.2.5. Recent Developments and Future Outlook
9.3. Spectrum Chemical Manufacturing
9.4. Actylis
9.5. Pfanstiehl
9.6. Biospectra
9.7. BOC Sciences

10. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

10.1. Chapter Overview
10.2. Merck KGaA
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Biopharmaceutical Excipient Offerings
10.2.4. Manufacturing Facilities
10.2.5. Recent Developments and Future Outlook
10.3. CG Chemkalien
10.4. Evonik
10.5. BASF Pharma

11. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC

11.1. Chapter Overview
11.2. Mass Chemicals
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Biopharmaceutical Excipient Offerings
11.2.4. Manufacturing Facilities
11.2.5. Recent Developments and Future Outlook
11.3. Gangwal
11.4. Mitushi Biopharma
11.5. Nagase Vitta

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Chapter Overview
12.2. Partnership Models
12.3. Biopharmaceutical Manufacturers: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Excipient
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Analysis by Geography
12.3.6.1. Local and International Agreements
12.3.6.2. Intracontinental and Intercontinental Agreements

13. RECENT EXPANSIONS

13.1. Chapter Overview
13.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
13.2.1. Analysis by Year of Expansion
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Year and Type of Expansion
13.2.4. Analysis by Type of Excipient
13.2.5. Analysis by Type of Expansion (Country)
13.2.6. Analysis by Location of Expanded Facility (Region)
13.2.7. Analysis by Location of Expanded Facility (Country)
13.2.8. Analysis by Type of Expansion and Location of Manufacturing Facility
13.2.9. Most Active Players: Analysis by Number of Recent Expansions
13.2.10. Geographical Analysis

14. CAPACITY ANALYSIS

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Location of Manufacturing Facility
14.4. Concluding Remarks

15. VENDOR SELECTION FRAMEWORK

15.1. Reasons to Outsource in Isotope Manufacturing
15.2. Commonly Outsourced Operations in Isotope Manufacturing
15.3. Key Parameters
15.4. Methodology for Vendor Selection Framework
15.5. Benchmarking of Parameters
15.6. Value Addition vs Evaluation Complexity Matrix
15.7. Case Study Assessment of Merck
15.8. Overview of Vendor Assessment Dashboard
15.8.1. Scenario I
15.8.2. Scenario II
15.8.3. Scenario III

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Biopharmaceutical Manufacturing Services Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.1. Roots Analysis Perspective on Market Growth
17.3.2. Scenario Analysis
17.3.2.1. Conservative Scenario
17.3.2.2. Optimistic Scenario
17.4. Key Market Segmentations

18. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY SCALE OF OPERATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Scale of Operation
18.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation

19. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY TYPE OF MODALITY

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Type of Modality
19.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Antibodies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3. Biopharmaceutical Excipients Manufacturing Services Market for Cell and Gene Therapies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.4. Biopharmaceutical Excipients Manufacturing Services Market for Proteins / Peptides, Historical Trends (since 2021) and Forecasted Estimate, (till 2035)
19.3.5. Biopharmaceutical Excipients Manufacturing Services Market for Other Biologics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation

20. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY TYPE OF EXCIPIENTS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Type of Excipient
20.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Buffering Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Lyoprotectant Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.3. Biopharmaceutical Excipients Manufacturing Services Market for Solubilizers and Surfactants, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.4. Biopharmaceutical Excipients Manufacturing Services Market for Tonicity Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.5. Biopharmaceutical Excipients Manufacturing Services Market for pH Adjusting Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.3.6. Biopharmaceutical Excipients Manufacturing Services Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation

21. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY CHEMICAL COMPONENTS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Chemical Components
21.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Carbohydrates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Polymers, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.3. Biopharmaceutical Excipients Manufacturing Services Market for Polyols, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.4. Biopharmaceutical Excipients Manufacturing Services Market for Proteins / Amino Acids, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
21.3.5. Biopharmaceutical Excipients Manufacturing Services Market for Others, Historical Trends (since 2021)and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY COMPANY SIZE

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Company Size
22.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Small Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
22.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Mid-sized Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
22.3.3. Biopharmaceutical Excipients Manufacturing Services Market for Large and Very Large Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY SOURCE OF MANUFACTURING

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Source of Manufacturing
23.3.1. Biopharmaceutical Excipients Manufacturing Services Market for In-house, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
23.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Outsourcing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY END USER

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by End User
24.3.1. Biopharmaceutical Excipients Manufacturing Services Market for Contract Manufacturers, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.3.2. Biopharmaceutical Excipients Manufacturing Services Market for Drug Developers, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.3.3. Biopharmaceutical Excipients Manufacturing Services Market for Hybrid Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation

25. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING SERVICES MARKET, BY GEOGRAPHICAL REGIONS

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biopharmaceutical Excipients Manufacturing Services Market: Distribution by Geographical Regions
25.3.1. Biopharmaceutical Excipients Manufacturing Services Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.1.1. Biopharmaceutical Excipients Manufacturing Services Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.1.2. Biopharmaceutical Excipients Manufacturing Services Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2. Biopharmaceutical Excipients Manufacturing Services Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.1. Biopharmaceutical Excipients Manufacturing Services Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.2. Biopharmaceutical Excipients Manufacturing Services Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.3. Biopharmaceutical Excipients Manufacturing Services Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.4. Biopharmaceutical Excipients Manufacturing Services Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.5. Biopharmaceutical Excipients Manufacturing Services Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.2.6. Biopharmaceutical Excipients Manufacturing Services Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3. Biopharmaceutical Excipients Manufacturing Services Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3.1. Biopharmaceutical Excipients Manufacturing Services Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3.2. Biopharmaceutical Excipients Manufacturing Services Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3.3. Biopharmaceutical Excipients Manufacturing Services Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3.4. Biopharmaceutical Excipients Manufacturing Services Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.3.5. Biopharmaceutical Excipients Manufacturing Services Market in Rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.4. Biopharmaceutical Excipients Manufacturing Services Market in Middle East and Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.4.1. Biopharmaceutical Excipients Manufacturing Services Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.4.2. Biopharmaceutical Excipients Manufacturing Services Market in UAE, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.4.3. Biopharmaceutical Excipients Manufacturing Services Market in Egypt, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.5. Biopharmaceutical Excipients Manufacturing Services Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.5.1. Biopharmaceutical Excipients Manufacturing Services Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.5.2. Biopharmaceutical Excipients Manufacturing Services Market in Mexico, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.3.5.3. Biopharmaceutical Excipients Manufacturing Services Market in Rest of Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
25.4. Biopharmaceutical Excipients Manufacturing Services Market , by Geographical Regions: Market Dynamics Assessment
25.4.1. Penetration Growth (P-G) Matrix
25.4.2. Market Movement Analysis
25.5. Data Triangulation and Validation

26. CONCLUDING INSIGHTS27. EXECUTIVE INSIGHTS28. APPENDIX I: TABULATED DATA29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Biopharmaceutical Excipient Manufacturers Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Properties of an Ideal Excipient
Figure 6.2 Classification of Biopharmaceutical Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
Figure 6.3 Applications of Biopharmaceutical Excipients
Figure 7.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Figure 7.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Figure 7.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters
Figure 7.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Figure 7.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Figure 7.6 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Figure 7.7 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Figure 7.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Figure 7.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Chemical Structure of Excipient
Figure 7.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Figure 7.11 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Figure 7.12 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Figure 8.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 8.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 8.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 8.4 Company Competitiveness Analysis: Biopharmaceutical Excipient Manufacturers Headquartered in North America (Peer Group I)
Figure 8.5 Company Competitiveness Analysis: Biopharmaceutical Excipient Manufacturers Headquartered in Europe (Peer Group II)
Figure 8.6 Company Competitiveness Analysis: Biopharmaceutical Excipient Manufacturers Headquartered in Asia-Pacific (Peer Group III)
Figure 9.1 Avantor: Consolidated: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
Figure 10.1 Merck KGaA: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since 2021
Figure 10.2 CG Chemkalien: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since 2021
Figure 10.3 Evonik: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since 2021
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2016
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Excipients
Figure 12.5 Most Active Players: Distribution by Number of Partnerships
Figure 12.6 Partnerships and Collaborations: Distribution by Country
Figure 12.7 Partnerships and Collaborations: Distribution by Region
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Type of Excipient
Figure 13.4 Recent Expansions: Distribution by Type of Expansion (Country)
Figure 13.5 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 13.6 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Figure 13.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 13.8 Recent Expansions: Distribution by Geography
Figure 14.1 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Figure 14.2 Biopharmaceutical Excipients Manufacturing Installed Global Capacity: Distribution by Company Size
Figure 14.3 Biopharmaceutical Excipients Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 14.4 Biopharmaceutical Excipients Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Region)
Figure 14.5 Biopharmaceutical Excipients Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country)
Figure 16.1 Global Biopharmaceutical Excipients Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
Figure 16.2 Global Biopharmaceutical Excipients Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 16.3 Global Biopharmaceutical Excipients Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 17.1 Global Biopharmaceutical Excipients Market: Distribution by Scale of Operation
Figure 17.2 Biopharmaceutical Excipients Market for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.3 Biopharmaceutical Excipients Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.1 Global Biopharmaceutical Excipients Market: Distribution by Type of Modality
Figure 18.2 Biopharmaceutical Excipients Market for Antibodies, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Biopharmaceutical Excipients Market for Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.4 Biopharmaceutical Excipients Market for Cell and Gene Therapies, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.5 Biopharmaceutical Excipients Market for Proteins / Peptides, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.6 Biopharmaceutical Excipients Market for Other Biologics, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 Global Biopharmaceutical Excipients Market: Distribution by Type of Excipient
Figure 19.2 Biopharmaceutical Excipients Market for Buffering Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Biopharmaceutical Excipients Market for Lyoprotectant Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Biopharmaceutical Excipients Market for Solubilizers and Surfactants, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.5 Biopharmaceutical Excipients Market for Tonicity Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.6 Biopharmaceutical Excipients Market for pH Adjusting Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.7 Biopharmaceutical Excipients Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.1 Global Biopharmaceutical Excipients Market: Distribution by Chemical Components
Figure 20.2 Biopharmaceutical Excipients Market for Carbohydrates, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.3 Biopharmaceutical Excipients Market for Polymers, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.4 Biopharmaceutical Excipients Market for Polyols, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.5 Biopharmaceutical Excipients Market for Proteins / Amino Acids, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.6 Biopharmaceutical Excipients Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.1 Biopharmaceutical Excipients Market: Distribution by Company Size
Figure 21.2 Biopharmaceutical Excipients Market for Small Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Biopharmaceutical Excipients Market for Mid-sized Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.4 Biopharmaceutical Excipients Market for Large and Very Large Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Biopharmaceutical Excipients Market: Distribution by Source of Manufacturing
Figure 22.2 Biopharmaceutical Excipients Market for In-house, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Biopharmaceutical Excipients Market for Outsourcing, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.1 Biopharmaceutical Excipients Market: Distribution by End-User
Figure 23.2 Biopharmaceutical Excipients Market for Contract Manufacturers, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Biopharmaceutical Excipients Market for Drug Developers, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Biopharmaceutical Excipients Market for Hybrid Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.1 Biopharmaceutical Excipients Market: Distribution by Geographical Regions
Figure 24.2 Biopharmaceutical Excipients Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 Biopharmaceutical Excipients Market in the US, Historical Trends (since 2021) and
Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 Biopharmaceutical Excipients Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 Biopharmaceutical Excipients Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.6 Biopharmaceutical Excipients Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.7 Biopharmaceutical Excipients Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.8 Biopharmaceutical Excipients Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.9 Biopharmaceutical Excipients Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.10 Biopharmaceutical Excipients Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.11 Biopharmaceutical Excipients Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.12 Biopharmaceutical Excipients Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.13 Biopharmaceutical Excipients Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.14 Biopharmaceutical Excipients Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.15 Biopharmaceutical Excipients Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.16 Biopharmaceutical Excipients Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.17 Biopharmaceutical Excipients Market in Rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.18 Biopharmaceutical Excipients Market in Middle East and Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.19 Biopharmaceutical Excipients Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.20 Biopharmaceutical Excipients Market in UAE, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.21 Biopharmaceutical Excipients Market in Egypt, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.22 Biopharmaceutical Excipients Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.23 Biopharmaceutical Excipients Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.24 Biopharmaceutical Excipients Market in Mexico, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.25 Biopharmaceutical Excipients Market in Rest of Latin America, Historical Trends (Forecasted Estimates (till 2035) (USD Million)
since 2021) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.26 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 24.27 Market Movement Analysis: Geographical Regions
Figure 25.1 Concluding Insights: Biopharmaceutical Excipient Manufacturers Market Landscape
Figure 25.2 Concluding Insights: Partnerships and Collaborations
Figure 25.3 Concluding Insights: Recent Expansions
Figure 25.4 Concluding Insights: Capacity Analysis
Figure 25.5 Concluding Insights: Biopharmaceutical Excipients Market Forecast and Opportunity Analysis

LIST OF TABLES

Table 6.1 Classification of Biopharmaceutical Excipients based on Function
Table 7.1 Biopharmaceutical Excipient Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 7.2 Biopharmaceutical Excipient Manufacturers: Information on Type of Excipient based on Chemical Composition and Function
Table 7.3 Biopharmaceutical Excipient Manufacturers: Information on Scale of Operation, Type of Formulation, Type of Excipient (based on Chemical Structure), Type of Biologic and Global Regulatory Compliance
Table 9.1 Biopharmaceutical Excipient Manufacturers in North America: List of Companies Profiled
Table 9.2 Avantor: Company Snapshot
Table 9.3 Avantor: Biopharmaceutical Excipient Offerings
Table 9.4 Avantor: Information on Manufacturing Facilities
Table 9.5 Avantor: Recent Developments and Future Outlook
Table 9.6 Spectrum Chemical Manufacturing: Company Snapshot
Table 9.7 Spectrum Chemical Manufacturing: Biopharmaceutical Excipient Offerings
Table 9.8 Spectrum Chemical Manufacturing: Information on Manufacturing Facilities
Table 9.9 Spectrum Chemical Manufacturing: Recent Developments and Future Outlook
Table 9.10 Actylis: Company Snapshot
Table 9.11 Actylis: Biopharmaceutical Excipient Offerings
Table 9.12 Actylis: Information on Manufacturing Facilities
Table 9.13 Actylis: Recent Developments and Future Outlook
Table 9.14 Pfanstiehl: Company Snapshot
Table 9.15 Pfanstiehl: Biopharmaceutical Excipient Offerings
Table 9.16 Pfanstiehl: Information on Manufacturing Facilities
Table 9.17 Pfanstiehl: Recent Developments and Future Outlook
Table 9.18 Biospectra: Company Snapshot
Table 9.19 Biospectra: Biopharmaceutical Excipient Offerings
Table 9.20 Biospectra: Information on Manufacturing Facilities
Table 9.21 Biospectra: Recent Developments and Future Outlook
Table 9.22 BOC Sciences: Company Snapshot
Table 9.23 BOC Sciences: Biopharmaceutical Excipient Offerings
Table 9.24 BOC Sciences: Information on Manufacturing Facilities
Table 9.25 BOC Sciences: Recent Developments and Future Outlook
Table 10.1 Biopharmaceutical Excipient Manufacturers in Europe: List of Companies Profiled
Table 10.2 Merck KGaA: Company Snapshot
Table 10.3 Merck KGaA: Biopharmaceutical Excipient Offerings
Table 10.4 Merck KGaA: Information on Manufacturing Facilities
Table 10.5 Merck KGaA: Recent Developments and Future Outlook
Table 10.6 CG Chemkalien: Company Snapshot
Table 10.7 CG Chemkalien: Biopharmaceutical Excipient Offerings
Table 10.8 CG Chemkalien: Information on Manufacturing Facilities
Table 10.9 CG Chemkalien: Recent Developments and Future Outlook
Table 10.11 Evonik: Company Snapshot
Table 10.12 Evonik: Biopharmaceutical Excipient Offerings
Table 10.13 Evonik: Information on Manufacturing Facilities
Table 10.14 Evonik: Recent Developments and Future Outlook
Table 10.15 BASF Pharma: Company Snapshot
Table 10.16 BASF Pharma: Biopharmaceutical Excipient Offerings
Table 10.17 BASF Pharma: Information on Manufacturing Facilities
Table 10.18 BASF Pharma: Recent Developments and Future Outlook
Table 11.1 Biopharmaceutical Excipient Manufacturers in Asia-Pacific: List of Companies Profiled
Table 11.2 Mass Chemicals: Company Snapshot
Table 11.3 Mass Chemicals: Biopharmaceutical Excipient Offerings
Table 11.4 Mass Chemicals: Information on Manufacturing Facilities
Table 11.5 Mass Chemicals: Recent Developments and Future Outlook
Table 11.6 Gangwal: Company Snapshot
Table 11.7 Gangwal: Biopharmaceutical Excipient Offerings
Table 11.8 Gangwal: Information on Manufacturing Facilities
Table 11.9 Gangwal: Recent Developments and Future Outlook
Table 11.10 Mitushi Bopharma: Company Snapshot
Table 11.11 Mitushi Biopharma: Biopharmaceutical Excipient Offerings
Table 11.12 Mitushi Biopharma: Information on Manufacturing Facilities
Table 11.13 Mitushi Biopharma: Recent Developments and Future Outlook
Table 11.14 Nagase Vitta: Company Snapshot
Table 11.15 Nagase Vitta: Biopharmaceutical Excipient Offerings
Table 11.16 Nagase Vitta: Information on Manufacturing Facilities
Table 11.17 Nagase Vitta: Recent Developments and Future Outlook
Table 12.1 Biopharmaceutical Excipient Manufacturers Market: List of Partnerships and Collaborations, Since 2016
Table 12.2 Partnerships and Collaborations: Information on Type of Agreement
Table 13.1 Biopharmaceutical Excipient Manufacturers Market: List of Expansions, Since 2020
Table 14.1 Capacity Analysis: Information on Company Size of Biopharmaceutical Excipient Manufacturers
Table 14.2 Capacity Analysis: Information on Average Capacity by Company Size
Table 14.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Total Capacity by Company Size
Table 28.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Table 28.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Table 28.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters
Table 28.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Table 28.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Table 28.6 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Table 28.7 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Table 28.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Table 28.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Chemical Structure of Excipient
Table 28.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Table 28.11 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Table 28.12 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Table 28.13 Avantor: Consolidated : Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
Table 28.14 Merck KGaA: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since
2021
Table 28.15 CG Chemkalien: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since 2021
Table 28.16 Evonik: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion), Since 2021
Table 28.17 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
Table 28.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 28.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2016
Table 28.20 Partnerships and Collaborations: Distribution by Type of Excipients
Table 28.21 Most Active Players: Distribution by Number of Partnerships
Table 28.22 Partnerships and Collaborations: Distribution by Country
Table 28.23 Partnerships and Collaborations: Distribution by Region
Table 28.24 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Table 28.25 Recent Expansions: Distribution by Type of Expansion
Table 28.26 Recent Expansions: Distribution by Type of Excipient
Table 28.27 Recent Expansions: Distribution by Type of Expansion (Country)
Table 28.28 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 28.29 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Table 28.30 Most Active Players: Distribution by Number of Recent Expansions
Table 28.31 Recent Expansions: Distribution by Geography
Table 28.32 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Table 28.33 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
Table 28.34 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 28.35 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Region)
Table 28.36 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country)
Table 28.37 Global Biopharmaceutical Excipients Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
Table 28.38 Global Biopharmaceutical Excipients Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 28.39 Global Biopharmaceutical Excipients Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 28.40 Global Biopharmaceutical Excipients Market: Distribution by Scale of Operation
Table 28.41 Biopharmaceutical Excipients Market for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.42 Biopharmaceutical Excipients Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.43 Global Biopharmaceutical Excipients Market: Distribution by Type of Modality
Table 28.44 Biopharmaceutical Excipients Market for Antibodies, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.45 Biopharmaceutical Excipients Market for Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.46 Biopharmaceutical Excipients Market for Cell and Gene Therapies, Historical
Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million) Table 28.47 Biopharmaceutical Excipients Market for Proteins / Peptides, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.48 Biopharmaceutical Excipients Market for Other Biologics, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.49 Global Biopharmaceutical Excipients Market: Distribution by Type of Excipient
Table 28.50 Biopharmaceutical Excipients Market for Buffering Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.51 Biopharmaceutical Excipients Market for Lyoprotectant Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.52 Biopharmaceutical Excipients Market for Solubilizers and Surfactants, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.53 Biopharmaceutical Excipients Market for Tonicity Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.54 Biopharmaceutical Excipients Market for pH Adjusting Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.55 Biopharmaceutical Excipients Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.56 Global Biopharmaceutical Excipient Market: Distribution by Chemical Components
Table 28.57 Biopharmaceutical Excipients Market for Carbohydrates, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.58 Biopharmaceutical Excipients Market for Polymers, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.59 Biopharmaceutical Excipients Market for Polyols, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.60 Biopharmaceutical Excipients Market for Proteins / Amino Acids, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Table 28.61 Biopharmaceutical Excipients Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.62 Biopharmaceutical Excipients Market: Distribution by Company Size
Table 28.63 Biopharmaceutical Excipients Market for Small Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.64 Biopharmaceutical Excipients Market for Mid-sized Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.65 Biopharmaceutical Excipients Market for Large and Very Large Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Figure 22.66 Biopharmaceutical Excipients Market: Distribution by Source of Manufacturing
Figure 22.67 Biopharmaceutical Excipients Market for In-house, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.68 Biopharmaceutical Excipients Market for Outsourcing, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.69 Biopharmaceutical Excipients Market: Distribution by End-User
Table 28.70 Biopharmaceutical Excipients Market for Contract Manufacturers, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.71 Biopharmaceutical Excipients Market for Drug Developers, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.72 Biopharmaceutical Excipients Market for Hybrid Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.73 Biopharmaceutical Excipients Market: Distribution by Geographical Regions
Table 28.74 Biopharmaceutical Excipients Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.75 Biopharmaceutical Excipients Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.76 Biopharmaceutical Excipients Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.77Biopharmaceutical Excipients Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035), ,Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.78 Biopharmaceutical Excipients Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.79 Biopharmaceutical Excipients Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)
Table 28.80 Biopharmaceutical Excipients Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.81 Biopharmaceutical Excipients Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) ,Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.82 Biopharmaceutical Excipients Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.83 Biopharmaceutical Excipients Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.84 Biopharmaceutical Excipients Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.85 Biopharmaceutical Excipients Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.86 Biopharmaceutical Excipients Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.87 Biopharmaceutical Excipients Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.88 Biopharmaceutical Excipients Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.89 Biopharmaceutical Excipients Market in Rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.90 Biopharmaceutical Excipients Market in Middle East and Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.91 Biopharmaceutical Excipients Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.92 Biopharmaceutical Excipients Market in UAE, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.93 Biopharmaceutical Excipients Market in Egypt, Historical Trends (since 2021) and
Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.94 Biopharmaceutical Excipients Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.95 Biopharmaceutical Excipients Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.96 Biopharmaceutical Excipients Market in Mexico, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 28.97 Biopharmaceutical Excipients Market in Rest of Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

A&C Bio Buffer
ABITEC
Actylis
Additive Manufacturing Customized Machines (AMCM)
Aditya Chemicals
ADM
Advancion (formerly known as ANGUS Chemical)
AmpTec
Apothecon Pharmaceuticals
Asahi Kasei
Ashland
Avanti Research
Avantor
Azelis
Barentz
BASF Pharma
BENEO
BIOGRUND
BioNTech
BioSpectra
BOC Sciences
Bonumose
Brenntag
Budenheim
Cascade Chemistry (acquired by Actylis)
CG Chemkalien
c-LEcta
Cole-Parmer
Colorcon
Corden Pharma
CPI
Crest Cellulose
Croda
DFE Pharma
DKSH
Dr. Paul Lohmann
DuPont
DURECT
Enmex
Erkang Pharmaceutical
Evonik
Finar
Fuji Chemical
Gangwal Healthcare
Gattefosse
Gelita
Harro Höfliger
Hawkins
HOPAX
Hosokawa Micron
Ideal Cures
IFF Pharma Solutions
IMCD
IMCoPharma
Indchem International
InnoCore Pharmaceuticals
International Flavors & Fragrances
InVitria
Itacel
JRS Pharma
Kerry
Kirsch Pharma
KLK Kolb
Kuraray
Larodan
Lazuline Biotech
LBB Specialties
Lipoid
Lubrizol
LyoHUB
Maas Pharma Chemicals
Meggle
Merck KGaA
Mitushi Biopharma
Moderna
Nagase Viita
National Institute of Bioprocessing Research and Training (NIBRT)
Nordic Bioproducts
Nordmann
PanReac AppliChem
PCAS
Pfanstiehl
Pfizer
Polykon Manufacturing
Qualicaps
ReForm Biologics
Roquette
Seppic
Shanghai Huamao Pharmaceutical
Shin-Etsu Chemical
Sigachi
Spectrum Chemical Manufacturing
SPI Pharma
Stanford University
Sudeep Pharma
TaBlitz
Thermo Fisher Scientific
Tomita
TTY Biopharm
Univar Solutions
VAV Life Sciences
Vikram Thermo
Wilshire Technologies

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4314EUR$4,799USD£3,744GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6291EUR$6,999USD£5,461GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16179EUR$17,999USD£14,044GBP